Is Amwill Health overvalued or undervalued?

As of 7 November 2025, Amwill Health's valuation grade has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued. Key ratios supporting this assessment include a PE ratio of 9.06, an EV to EBIT of 7.64, and an ROCE of 18.23%.
In comparison to its peers, Amwill Health's valuation metrics stand out, particularly against Sun Pharma, which is deemed expensive with a PE ratio of 35.17, and Divi's Lab, classified as very expensive with a PE ratio of 71.11. This stark contrast highlights Amwill Health's attractive valuation within the pharmaceuticals and biotechnology sector. Additionally, while Amwill Health has experienced a decline in stock price recently, it remains undervalued relative to its peers, reinforcing the potential for future upside.